Trial Profile
XePOHCAS: Prospective, randomized, multicenter, interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management [TTM]) to standard-of-care post-cardiac arrest intensive care (including TTM) plus xenon by inhalation
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs Xenon (Primary)
- Indications Chronic brain damage
- Focus Registrational; Therapeutic Use
- Acronyms XePOHCAS
- Sponsors NeuroproteXeon
- 16 Feb 2019 This trial has been Suspended in Denmark (end date: 2018-06-26)
- 08 Feb 2019 Status changed from active, no longer recruiting to recruiting.
- 10 Jan 2019 Status changed from recruiting to active, no longer recruiting.